



Implement a Drug Repurposing Infrastructure
Identify & Validate New Use Hypotheses Systematically
Transform Clinical Failures into Successes

Engage With Expert Speakers Including:



DAVID BROWN
Healx Ltd



ARIS PERSIDIS
Biovista




CRAIG WEGNER
AstraZeneca



CHRISTINE COLVIS
NIH/NCATS



MARK HURLE
GSK



CHRIS GIBSON
Recursion Pharmaceuticals

Benefits of Attending

Systematically Convert Portfolio Failures into Clinical Successes

Identify new disease indications for existing compounds and approved drugs

Systematic DRPx enables you to systematically repurpose failed, shelved and existing drugs for their true disease indication to dramatically improve clinical outcomes and **maximize true commercial value**. Sidestep drug development bottlenecks, dramatically improve compound and target identification, and extract additional value from pre-existing R&D investments.

Systematic DRPx Summit will address how drug repurposing can become a core component of your R&D by demonstrating when and how to implement a successful strategy. Learn to de-risk the **transformation of previous failures** into future clinical and commercial success from industry leaders including AstraZeneca and Biovista.

Leading experts from GSK, NIH and CureHunter will demonstrate how advanced **high-throughput screening platforms** and analytics have streamlined a systematic drug repurposing approach to rescue shelved compounds and optimize existing drugs.

This summit will provide drug developers with a platform to discuss strategies to **optimize ROI on failed portfolio assets**, and through case study-driven talks to accurately position your drug for the correct disease indication from the outset.

Now is the time to seize the opportunity of DRPx and fuel future innovation to successfully manage and prioritize your portfolio assets.

5 Key Benefits to Takeaway

- 1 **Systematically** evaluate the potential of your shelved compounds and drugs for successful disease indication expansion
- 2 Harness optimal **hypothesis identification and validation** strategies to generate new indications for shelved compounds and existing drugs
- 3 Discover effective **big data** protocols to identify the most promising compounds and targets to progress further into clinical development
- 4 Understand the **IP landscape** to expand into new indications and strategically optimize ROI for your portfolio assets
- 5 Enhance **external collaborations** to accelerate identification of new indications for compounds and to progress pilot studies for further clinical development

5 Key Ideas to Implement

- 1 Create a sustainable **infrastructure** that supports effective strategic repurposing of your compounds and drugs
- 2 Utilize advanced **high throughput screening** platforms and strategies to optimize repurposing of discontinued shelved compounds
- 3 Expand current portfolio assets through strategic indication expansion using **individual case studies** from industry leaders as successful frameworks to fuel innovation
- 4 Optimize and adapt your current drug discovery through reproducible strategies to accurately identify the **right disease indication** the first time round
- 5 Fuel innovation of your assets for indication expansion into **rare and neglected diseases** by using successfully implementing drug repurposing as a core strategy

Speakers



David Brown
Chairman, Co-Inventor of
Viagra (Pfizer)



Aris Persidis
President, Editor in Chief,
Journal of Drug Repurposing,
Rescue, and Repurposing




Daniel Gil
Vice President, Research
Technologies and Research
Portfolio Lead



Craig Wegner
Head, Boston Emerging
Innovations Unit, Scientific
Partnering & Alliances



Christine Colvis
Director, Drug Development
Partnership Programs



Mark Hurle
Director of Computational
Biology, Systematic Drug
Repositioning



Felix Sheinerman
Chief Scientific Officer



Jordan Miller
Associate Professor
of Physiology



T. Jake Liang
Senior Investigator, Chief
of Liver Diseases Branch
and Deputy Director of
Translational Research




Stephen Wong
Chair and Professor,
Department of
Systems Medicine and
Bioengineering, Weill Cornell
Medical College




Usman Iqbal
Senior Medical Affairs,
Neurosciences



Chris Gibson
Chief Executive Officer




Charles Niebylski
Strategic Alliances
Manager, Office of
Strategic Alliances



Judge Schonfeld
CEO and Chief Scientist,
CureHunter Inc



Eleftherios Mylonakis
Dean's Professor of Medical
Science, Chief, Infectious
Diseases Division



David Cavalla
Chief Scientific Officer



■ This summit covers the key technologies, provides opportunity to explore practical implementation, and opportunity to meet the companies driving this new wave of innovation.

Repositioning technologies are maturing rapidly and will add tremendous value to clinical candidate drugs. They have the potential to solve problems that have hampered earlier stage drug discovery historically pursued by phenotypic and target-based methods and can by-pass weaknesses of the older methods ■

David Brown on Systematic DRPx 2015

Linked in

SEARCH GROUPS FOR:
Systematic Drug Repositioning
to join the online community.

Conference Day One

Wednesday October 21st 2015

8.00 **Registration & Breakfast**

9.00 **Chair's Opening Remarks**

David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

When and How to Implement Systematic Drug Repurposing?

9.10 **Keynote Interview: Establishing a Systematic Approach to Drug Repurposing - What Needs To Be Done?**

Get an exclusive insight from those developing and implementing strategies to systematically repurpose drugs/compounds. The panel will discuss and answer the following questions:

- How can you make systematic drug repurposing a core component of your portfolio strategy?
- On what basis should a hypothesis be put forward to identify a new indication?
- What are the current strategies in place for successful systematic drug repurposing?
- Which disciplines need to come together to drive forward repurposing efforts?
- What can the industry learn from the latest patent cases involving repurposing of existing assets?

Moderator: David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

Aris Persidis, President, **Biovista**, Editor in Chief, **Journal of Drug Repurposing, Rescue, and Repurposing**

Daniel Gil, Vice President, Research Technologies and Research Portfolio Lead, **Allergan**

Craig Wegner, Head, Boston Emerging Innovations Unit, Scientific Partnering & Alliances, **AstraZeneca**

Christine Colvis, Director, Drug Development Partnership Programs, **National Institute of Health Sciences**

T. Jake Liang, Chief of Liver Diseases Branch and Deputy Director of Translational Research, **NIH**

10.10 **Keys to the Successful Implementation of Systematic Drug Repurposing Within Pharma**

- What are the major benefits of drug repurposing?
- What are the major risks, costs and other challenges?
- Examples of how the above can be successfully balanced- where benefits outweigh risks and costs

Craig Wegner, Head, Boston Emerging Innovations Unit, Scientific Partnering & Alliances, **AstraZeneca**

10.40 **Morning Refreshments & Speed Networking**

11.40 **Practicing Repurposing in the Real World: Overcoming the Lack of Knowledge & Applied Examples**

- Overcoming challenges with the real-world context of a patient, who may have complications, confounders and comorbidities
- A holistic approach to systematic repurposing will be discussed, including financial, IP, and examples

Aris Persidis, President, **Biovista**, Editor in Chief, **Journal of Drug Repurposing, Rescue, and Repurposing**

12.10 **Systematization of Drug Repurposing**

- Describe various strategies employed for systematizing drug re-discovery
- Describe our own target-agnostic strategy for parallelizing high-content phenotypic assays (phenomics)
- Case studies on initial successes with our system
- Discussion of the opportunities and challenges associated with phenomics-based drug re-discovery

Chris Gibson, Co-Founder and CEO, **Recursion Pharmaceuticals**

12.40 **Networking Lunch**

Technology Implementation: Optimizing Screening Strategies for Indication Expansion

1.40 **Repurposing of Drugs for Therapeutic Development of HCV Infection**

- Learn about the cell-based high-throughput screen for discovery of drugs against HCV
- Discover the mechanism of action of antihistamine compounds as anti-HCV drugs
- Hear about the therapeutic repurposing and re-derivation of these drugs for HCV therapy

T. Jake Liang, Chief of Liver Diseases Branch and Deputy Director of Translational Research, **NDDK, NIH**

2.10 Discovery Using Computational Chemogenomics Technology and Clinical Demonstration of Activity of a First-in Class Therapeutic: Topically Bioavailable Selective Kit Kinase Inhibitor

- Learn about computational technology for systematic “drug retargeting”, which resulted in identification of previously unrecognized targets of small molecule drugs, leading to new therapeutic opportunities
- How to use this technology to identify clinically tested drugs acting on important signaling targets unrelated to the previously known targets of these drugs
- Presentation on the activity of nPharmakon’s most advanced development candidate for a new indication confirmed in a double-blind clinical study completed in 2014

Felix Sheinerman, Chief Scientific Officer,
nPharmakon LLC

2.40 Systematic Drug Repositioning: Targeting, Triaging, Testing

- Developing flexible information management and integration, dependence on individual workstreams
- Identifying relationships from new data sources
- Learnings from low-medium throughput screening strategies (*in vitro* and *in vivo*)

Mark Hurle, Director of Computational Biology,
Systematic Drug Repositioning, **GSK**

3.10 Computing a New Cure For Ebola or Alzheimer in 4 Minutes Flat: A CureHunter AI Systems Biology Machine Case History

- How to learn from and apply CAD-ME and EE industry system development models to building a completely digital molecule to medicine pathway for de novo drug discovery and DRPx
- How to integrate High Throughput Knowledge Screening with classical wet chemistry technologies to make the most of the capabilities of breakthrough and traditional methods
- How to ensure high ROI with early phase in silico modeling using clinical efficacy predictions to pre-empt futile paths and “get it right the first time”

Judge Schonfeld, CEO and Chief Scientist,
CureHunter Inc

3.40 Afternoon Refreshments

4.10 Systematic DRPx Mastermind Roundtables : Adding Value to Existing Assets

Tap into your peers’ wealth of expertise during this interactive session, who will discuss the following areas:

- Fundamental requirements for progressing initial hypotheses from a big data perspective - how to identify the most promising hypotheses to progress further
- Intellectual Property- how is it influencing the progression of systematic drug repurposing?
- Moving away from ad hoc & fragmented implementation – how to you incorporate DRPx into your portfolio strategy
- Enhancing pharma and academic collaborations for optimal new disease indication-merging different cultures

Moderators: Usman Iqbal, Senior Medical Affairs,
Neurosciences, **AstraZeneca**

David Brown, Chairman, Co-Inventor of Viagra (Pfizer),
Healx Ltd

Charles Niebyski, Strategic Alliances Manager, Office
of Strategic Alliances, **NCATS, NIH**

Jordan Miller, Associate Professor of Physiology,
Mayo Clinic

5.10 Chair’s Closing Remarks

David Brown, Chairman, Co-Inventor of Viagra (Pfizer),
Healx Ltd

5.15 Close of Day 1

“Very carefully chosen content and very informative. It is the right balance between industry and academia”

Takeda



Conference Day Two

Thursday October 22nd 2015

8.00 Breakfast & Networking

9.00 Chair's Opening Remarks

David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

IP For Indication Expansion

9.10 Tackling The Elephant in the Room: Who Owns the IP?

- Strategically evaluating if the exclusivity of the IP will have sufficient duration in the market to justify the cost of development
- Repositioning or repurposing therapeutics for rare diseases provides valuable non-patent exclusivities and often serendipitously uncovers IP or knowledge relevant to more common diseases and Human Health
- Recent shifts in IP law and collaborative models: Emerging Paths for the Drug Development Ecosystem and examples of success

Charles Niebylski, Strategic Alliances Manager, Office of Strategic Alliances, NCATS, **NIH**

9.35 One Size Does Not Fit All – What are the Best Examples to Illustrate Common IP Exclusivity Challenges and Opportunities in Drug Repurposing

- How can we assess the IP landscape for individual examples in expanding into new indications?
- What are the key regulatory factors that may inhibit innovation within re-drug discovery for existing assets?

Interactive Panel discussion and Open Q&A

Moderator: **David Brown**, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

Panelists: **Charles Niebylski**, Strategic Alliances Manager, Office of Strategic Alliances, **NCATS, NIH**

Jordan Miller, Associate Professor of Physiology, **Mayo Clinic**

10.00 Keynote Session: Weaknesses in Phenotypic and Target-Based Drug Discovery: Can DRP Technologies Avoid the Same Old Problems?

- Highlighting the phenotypic approaches dominated until 1990s, and the major weaknesses leading to high failure rates in human clinical trials
- How target-based approaches were adopted but often failed to solve the problems, and introduced new issues
- Can our new technologies applicable to drug repurposing overcome the weaknesses of these two old approaches?
- Case studies from Aspirin to Viagra will illustrate the issues and realities of drug repurposing

David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

11.00 Morning Refreshments

Drug Repurposing in Action: Strategic Portfolio-Based Indication Expansion

11.30 Planned Serendipity: Repurposing with Local Therapy

- What are the strategic, cultural and organizational elements that lead to a successful repurposing mindset?
- How are we evolving our model to take advantage of new datasets?
- Case studies of successful repurposing of both internal and external drugs will be presented

Daniel Gil, Vice President, Research Technologies and Research Portfolio Lead, **Allergan**

12.00 Antimicrobial Drug Discovery and Repurposing Using a Whole Animal *C. elegans*-Based HTS

- Highlighting the nematode *Caenorhabditis elegans* model to study microbial pathogenesis in a genome-wide scale and perform whole-animal, high throughput bioassays for novel antimicrobial compounds. his whole animal infection model can identify compounds that cure infections associated with resistant pathogens
- Describing how this screening model permits data-driven decisions regarding the quality of a hit and eliminates preconceived biases about certain chemical classes or motifs
- How the whole-animal *in vivo* assay examines some compound characteristics (such as water solubility, stability and toxicity) in parallel and avoids inefficiencies optimization hits with regard to desired properties, which must occur in a traditional optimization cycle

Eleftherios Mylonakis, Dean's Professor of Medical Science, Chief, Infectious Diseases Division, **Brown University**

12.30 Rational Rarepurposing For Childhood Cancers

- Addressing the issues with existing chemotherapeutic agents for childhood cancers
- Applying algorithmic methods of predicting new uses based on gene expression profiles (validated in leukemia)
- Cross-comparing profiles of childhood cancers to profiles of approved drugs to identify rarepurposing candidates
- Candidate validation using established *in vitro* cell assays

David Cavalla, Chief Scientific Officer, **Healx Ltd**

1.00 Networking lunch

2.00 DrugX platform – Using Big Data Analytics and Systems Biology Modeling for Achieving Faster Cures

- Introduce strategies for systematic drug repositioning using the large public pharmacogenomics datasets
- Present algorithms of combining DrugX platform with genomics and other biomarkers to support precision medicine
- Showcase a few success stories based on DrugX engine on drug repositioning

Stephen Wong, Chair and Professor, Department of Systems Medicine and Bioengineering, Weill Cornell Medical College Houston, **Methodist Research Institute**

2.30 Matching the Right Compound to the Right Investigator

- Developing strategies to enhance the awareness of compounds to ensure relevant researchers submit a proposal
- Facilitating communication and building relationships between pharma, biotechs and academics
- What have we learned so far from pilot studies

Christine Colvis, Director, Drug Development Partnership Programs, **National Institute of Health Sciences**

3.00 Accelerated Drug Repurposing in Academia: New Perspectives on Strategies to Summit Mount Improbable

- Understand intellectual property and its usefulness in preliminary drug repurposing discussions
- Develop infrastructure to support rapid drug repurposing in academia
- Design pre-clinical and clinical studies that add value to industry partners
- Understand the need to address regulatory hurdles associated with getting a drug to market early on in the process

Jordan Miller, Associate Professor of Physiology, **Mayo Clinic**

3.30 Afternoon Refreshments

4.00 Roundtable Intelligence & Mastermind Discussion

Missed a roundtable you wished you were at or have unanswered questions to your specific challenges? Fear not as roundtable moderators summarize the key industry intelligence from the earlier discussions on the key areas including optimizing screening strategies for drug repurposing, developing the right infrastructure to facilitate indication expansion and understanding and solving the IP challenges. This is one final opportunity to outline key future trends for the field:

- What ways can the industry enhance their current strategies to develop a systematic approach to capitalize on their assets?
- What are the key takeaways this industry needs to take on board to successfully repurpose drugs?
- What technologies are poised to exploit drug promiscuity?
- What are main IP challenges that need to be considered before initiating drug repurposing?

Moderator: David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

Usman Iqbal, Senior Medical Affairs, Neurosciences, **AstraZeneca**

Charles Niebylski, Strategic Alliances Manager, Office of Strategic Alliances, **NCATS, NIH**

Jordan Miller, Associate Professor of Physiology, **Mayo Clinic**

4.30 Chair's Closing Remarks

David Brown, Chairman, Co-Inventor of Viagra (Pfizer), **Healx Ltd**

4.35 Close of Congress

Partnership Opportunities

Why partner with us?

- Present your solution in front of 70 VPs, Directors, and Heads of Portfolios from Research & Development discovery
- Educate the industry on your product or service by joining our expert speaker faculty and showcase the value of your solutions
- Maintain your position as a thought leader within the Drug Repositioning arena
- Network with new clients and cement existing relationships via our speed networking, personal introductions and our multiple industry wide touch points
- Discuss industry-defining strategies with over 20 of the leading Drug Repositioning companies
- Wish-list of your choice contacted, in advance of the conference, to help ensure that your hottest prospects are in the room

Members of the Life Science Community



Become a Commercial Partner

Contact **Liam Wedderburn**
Business Development

Tel: +44 (0)203 141 8783 **Email:** liam.wedderburn@hansonwade.com

What our customers say

“I could not be more enthusiastic in my description of how useful it was. The talks were timely and relevant to our concerns, but, more importantly, the organized networking opportunities were the best I have experienced in a professional meeting. Bravo on the ‘speed dating!’”

As a result of the meeting we **currently are involved in active negotiations** with three companies we met there and are in question-answering stage with others. Almost too much interest for us to handle!”

MD, Director, Washington University School of Medicine

Pricing & Venue

Venue & Accommodation:

Boston Park Plaza

50 Park Plaza at Arlington
Street
Boston, MA 02116

Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.



Great program, speakers and panelists, which will lead to productive discussions, networking and exchange of ideas

MedImmune

Pricing

Register

www.systematic-drp.com/register

Tel: +1 212 537 5898

Email: register@hansonwade.com

Mail:

Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU

Team Discounts

- **10% discount** – 3 delegates
- **15% discount** – 4 delegates
- **20% discount** – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

	Register & Pay before Friday July 10th 2015*	Register & Pay before Friday August 14th 2015*	Register & Pay before Friday September 18th 2015*	Standard Prices
Industry	\$1999 (save \$600)	\$2199 (save \$400)	\$2399 (save \$200)	\$2599
Academic	\$1299 (save \$300)	\$1399 (save \$200)	\$1499 (save \$100)	\$1599

Top 3 Benefits of Attending Systematic DRPx 2015:

- 1 Systematically turn your failed compounds into successes
- 2 Maximize the commercial potential of your existing assets
- 3 Reduce your failure rate and de-risk your drug discovery

Terms & Conditions

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

* 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.